Ambrisentan for the management of pulmonary arterial hypertension

Clinical Therapeutics

Volumn 30, Issue 5, 2008, Pages 825-833

  Cheng, Judy W M ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

ambrisentan; endothelin receptor antagonist; pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; BOSENTAN; CLARITHROMYCIN; ILOPROST; ITRACONAZOLE; LETAIRIS; OMEPRAZOLE; PLACEBO; PROSTACYCLIN; RIFAMPICIN; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CONSTIPATION; COUGHING; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART PALPITATION; HUMAN; LEG EDEMA; MEDLINE; NAUSEA; NONHUMAN; NOSE CONGESTION; PUBLICATION; PULMONARY HYPERTENSION; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SUDDEN DEATH; TERATOGENICITY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WORLD HEALTH ORGANIZATION;

ANIMALS; DRUG INTERACTIONS; FEMALE; HEPATIC INSUFFICIENCY; HUMANS; HYPERTENSION, PULMONARY; LACTATION; MALE; PHENYLPROPIONATES; PREGNANCY; PYRIDAZINES; RECEPTOR, ENDOTHELIN A; RENAL INSUFFICIENCY;

EID: 44949089427     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.05.005     Document Type: Article

References (46)

1. Newman J., Fanburg B., Archer S., et al., for the National Heart, Lung, and Blood Institute/Office of Rare Diseases. Pulmonary arterial hypertension: Future directions: Report of a National Heart, Lung, and Blood Institute/Office of Rare Diseases workshop. Circulation 109 (2004) 2947-2952
2. Simonneau G., Galiè N., Rubin L., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl S (2004) 5S-12S
3. McLaughlin V., and McGoon M. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
4. Packer M. Therapeutic application of calcium-channel antagonists for pulmonary hypertension. Am J Cardiol. 55 (1985) 196B-201B
5. Letairis (ambrisentan) tablets for oral use. Full prescribing information.
6. (November 13, 2007). http://www.letairis.com/downloads/LETAIRIS_prescribing_information.pdf Accessed
7. Farber H., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655-1665
8. Levin E. Endothelins. N Engl J Med 333 (1995) 356-363
9. Parker J., Thiessen J., Reilly R., et al. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther 289 (1999) 261-265
10. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
11. Ellahham S., Charlon V., Abassi Z., et al. Bosentan and the endothelin system in congestive heart failure. Clin Cardiol 23 (2000) 803-807
12. Kaddoura S., Firth J., Boheler K., et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 93 (1996) 2068-2079
13. Muller D., Mervaala E., Schmidt F., et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36 (2000) 282-290
14. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
15. Nootens M., Kaufmann E., Rector T., et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26 (1995) 1581-1585
16. Bauer M., Wilkens H., Langer F., et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105 (2002) 1034-1036
17. Vatter H., Zimmermann M., Jung C., et al. Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery. Clin Sci (Lond). 103 Suppl 48 (2002) 408S-413S
18. Tracleer (bosentan tablets) 62.5 and 125 mg film-coated tablets.
19. (November 15, 2007). http://www.tracleer.com/pdf/PI_4pg_TR2454_032707_FINAL.pdf?kw=bosentan Accessed
20. Center for Drug Evaluation and Research. Application number 22-081. Pharmacology review.
21. (March 3, 2008). http://www.fda.gov/cder/foi/nda/2007/022081s000_PharmR_P1.pdf Accessed
22. Galiè N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
23. Gerber M., Dufton C., Pentikis H., et al. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest 130 Suppl 4 (2006) 256S Abstract
24. Dufton C., Gerber M., Yin O., et al. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest. 130 Suppl 4 (2006) 254S Abstract
25. Oudiz R., Torres F., Frost A., et al. ARIES-1: A placebo controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Chest 130 Suppl 4 (2006) 121S Abstract
26. Olschewski H, Galiè N, Kramer M, Rubin LJ, for the ARIES-2 Study Group. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 Study. Abstract C85.
27. (November 17, 2007). http://www.abstracts2view.com/ats06/view.php?nu=ATS06L_3398 Accessed
28. Barst R. A review of pulmonary arterial hypertension: Role of ambrisentan. Vasc Health Risk Manage 3 (2007) 11-22
29. D'Alonzo G., Barst R., Ayres S., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
30. Center for Drug Evaluation and Research. Application number 22-081. Medical review.
31. (March 3, 2008). http://www.fda.gov/cder/foi/nda/2007/022081s000_MedR_P1.pdf Accessed
32. Oudiz R., et al. Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension. Chest 132 (2007) 474a Abstract
33. McGoon M, Frost A, Rubin L, for the Ambrisentan in PAH Study Group. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities: 1 Year follow-up. Abstract B15.
34. (November 18, 2007). http://www.abstracts2view.com/ats07/view.php?nu=ATS07L_2171&terms Accessed
35. x Alert. June 2007.
36. (November 18, 2007). https://www.caremark.com/portal/asset/TrendsRxSpecialtyAlert_Letairis.pd f Accessed
37. Kenyon K., and Nappi J. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 37 (2003) 1055-1062
38. Anderson SL, Heberlig RM, Koons K. The pharmacologic management of primary pulmonary hypertension. May 2003.
39. (November 18, 2007). vhttp://www.pbm.va.gov/criteria/Primary%20Pulmonary%20Hypertension.pdf Accessed
40. Cheever K., Kitzes B., and Genthner D. Epoprostenol therapy for primary pulmonary hypertension. Crit Care Nurse 19 (1999) 20-27
41. Pulmonary Hypertension Association. Iloprost (Ventavis) fact sheet.
42. (November 18, 2007). http://www.phassociation.org/Learn/treatment/iloprost.asp Accessed
43. Letairis (ambrisentan) 5 mg and 10 mg tablets. How to get Letairis.
44. (November 18, 2007). http://www.letairis.com/how_to_get_letairis.html Accessed
45. Nakov R., Pfarr E., Eberle S., and for the HEAT Investigators. Darusentan: An effective endotheline A receptor antagonist for treatment of hypertension. Am J Hypertens 15 (2002) 583-589
46. Cheng J. Tezosentan in the management of decompensated heart failure. Cardiol Rev 13 (2005) 28-34